CLAIMS


1. Dapagliflozin for use in the treatment of chronic kidney disease (CKD) in a patient that does not have Type 2 diabetes.

2. Use of dapagliflozin in the manufacture of a medicament for treating chronic kidney disease (CKD) in a patient that does not have Type 2 diabetes.

3. Dapagliflozin for use according to claim 1 or the use of claim 2, wherein the use is in a patient that has an eGFR ≥25 and ≤75 mL/min/1.73m^2.

4. Dapagliflozin for use according to claim 1 or the use of claim 2, wherein the dapagliflozin is in the form of a non-crystalline solid or wherein the dapagliflozin is in the form of a crystalline solid.

5. Dapagliflozin for use or the use according to any of claims 1 - 3, wherein the dapagliflozin is in the form of a (S)-propylene glycol ((S)-PG) solvate that has the structure



6. Dapagliflozin for use or the use according to any one of the preceding claims, wherein the dapagliflozin is in the form of a tablet for oral administration.

7. Dapagliflozin for use or the use according to any one of the preceding claims, wherein the dapagliflozin is to be administered in a dosage of 2.5 mg/day, 5 mg/day, or 10 mg/day.

8. Dapagliflozin for use or the use according to any one of the preceding claims, wherein the dapagliflozin is to be administered in a dosage of 10 mg/day.

9. Dapagliflozin for use or the use according to any one of the preceding claims, wherein the dapagliflozin is to be administered once daily.

10. Dapagliflozin for use or the use according to any one of the preceding claims, wherein the use is in a patient that has CKD with albuminuria.

11. Dapagliflozin for use or the use according to claim 10, wherein the use is in a patient that has a urine albumin creatinine ratio [UACR] ≥200 and ≤5000 mg/g.

12. Dapagliflozin for use or the use according to any one of the preceding claims, wherein the use is capable of reducing the incidence of a composite endpoint of ≥50% sustained decline in eGFR, reaching end-stage renal disease (ESRD), CV death, or renal death in a patient with CKD.

13. Dapagliflozin for use or the use according to claim 12, wherein the use is capable of reducing the incidence of the primary composite endpoint of ≥50% sustained decline in eGFR, reaching ESRD, CV death, or renal death when added to current background therapy in a patient with CKD and albuminuria.

14. Dapagliflozin for use or the use according to any one of the preceding claims, wherein the use is capable of decreasing intra-glomerular pressure, hypertension, proteinuria, and/or fluid/sodium overload in the patient.